Genetic polymorphisms of interleukin 1β gene and sporadic pancreatic neuroendocrine tumors susceptibility

Dimitrios Karakaxas, Anna Sioziou, Gerasimos Aravantinos, Ahmet Coker, Ioannis S Papanikolaou, Theodoros Liakakos, Christos Dervenis, Maria Gazouli

AIM: To evaluate the association between the interleukin 1β (IL-1β) polymorphisms and the pancreatic neuroendocrine tumor (pNET) development.

METHODS: A case-control study was conducted analyzing IL-1β polymorphisms using germline DNA collected in a population-based case-control study of pancreatic cancer (51 pNET cases, 85 pancreatic ductal adenocarcinoma cases, 19 intraductal papillary mucinous neoplasm and 98 healthy controls).

RESULTS: The distribution of genotypes for the -511
C/T polymorphism in the pNET patient groups showed significant difference compared to the control group. It is known that the carriers of the IL-1β -511T allele have increased concentrations of IL-1β. The -511 CT and TT high-expression genotypes were over-represented in pNET patients.

CONCLUSION: The findings of this study suggested a possible role of IL-1β -511 C/T genotypes in the pathogenesis of pNETs since the presence of the IL-1β -511 CT and TT genotypes and the T allele was associated with an increased risk of pNET only.

Key words: Interleukin 1β; Neuroendocrine tumors; Pancreas

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Pancreatic neuroendocrine tumors (pNETs) are a heterogeneous group of rare neoplasms derived from pancreatic endocrine cells and have significantly different tumor biology and present better prognosis compared with tumors of the exocrine pancreas, like pancreatic adenocarcinomas. It is widely accepted that chronic inflammation contributes to pathogenesis of many pancreatic diseases, including pancreatic carcinogenesis. Interleukin 1β (IL-1β) is a highly active pro-inflammatory cytokine with multiple biological effects, such as directing cancer cells to either neuroendocrine differentiation or to development of adenocarcinoma. The purpose of the study was to evaluate the association between the IL-1β polymorphisms and the pNET development.

Karakaxas D, Sioziou A, Aravantinos G, Coker A, Papanikolaou IS, Liakatos T, Dervenis C, Gazouli M. Genetic polymorphisms of interleukin 1β gene and sporadic pancreatic neuroendocrine tumors susceptibility. World J Gastrointest Oncol 2016; 8(6): 520-525 Available from: URL: http://www.wjgnet.com/1948-5204/full/v8/i6/520.htm DOI: http://dx.doi.org/10.4251/wjgo.v8.i6.520

INTRODUCTION
Pancreatic neuroendocrine tumors (pNETs) are a heterogeneous group of rare neoplasms derived from pancreatic endocrine cells[1-5]. The annual incidence of pNETs is estimated to be approximately 3.65 per 100000 individuals in the United States and occur sporadically or may be associated with genetic syndromes such as multiple endocrine neoplasia type 1 (MEN-1), von Hippel-Lindau syndrome (VHL), von Recklinghausen disease (neurofibromatosis NF-1), and tuberous sclerosis complex (TSC)[6-8].

PNETs are mainly considered functionally inactive tumors, but when related with hormone or peptide overproduction, such as insulin, gastrin, glucagon, vasoactive intestinal polypeptide (VIP) and somatostatin they are responsible for many characteristic clinical syndromes, with insulinoma being the most common PNETs are usually asymptomatic[9,10], have significantly different tumor biology, and present better prognosis compared with tumors of the exocrine pancreas, like pancreatic adenocarcinomas (PDACs)[11].

The molecular basis of pNETs pathogenesis is poorly characterized but several recent reports have been conducted in order to clarify their etiology[12].

It is widely accepted that chronic inflammation contributes to pathogenesis of many pancreatic diseases, including pancreatic carcinogenesis[13,14]. However, the exact mechanism by which chronic inflammation promotes carcinogenesis is still unknown. During carcinogenesis the host-mediated anti-tumor activity is suppressed, whereas pro-inflammatory events support tumor growth, angiogenesis, invasion and metastasis[15-17]. The inflammatory response is mediated by cytokines, which are glycoproteins or soluble proteins and their role in cancer immunity and carcinogenesis has been well established[18-20].

Neuroendocrine tumors express various cytokines and growth-factors. Several pro-inflammatory cytokines have been found in pNETs tissue suggesting their involvement in pNET development[18-21]. Additionally, numerous studies suggested that gastroenteropancreatic-NETs occur more frequently in the environment of chronic inflammation[22-24]. Thus, cytokines such as interleukin 1 (IL-1) poses an important role in neuroendocrine tumors since direct cancer cells to either neuroendocrine differentiation or to development of adenocarcinoma. Exogenously added IL-1 results in a decrease of chromogranin A (CgA) and simultaneous increase in carcinomembrane antigen (CEA) secretion[25].

IL-1β is a highly active pro-inflammatory cytokine with multiple biological effects[26]. IL-1β protein levels are related to the intensity of the inflammatory response, and regarding to pancreas, IL-1β is implicated in cancer progression, especially tumor invasiveness, metastasis and angiogenesis[27,28].

The IL-1β gene is located in the IL1 cluster on chromosome 2q and several single nucleotide polymorphisms (SNPs) of this gene influence the regulation of its expression and function have been studied[29-32]. There are two SNPs in the proximal promoter region of the IL-1β gene, -511 C/T and +3954 T/C, which both have been correlated with gastrointestinal cancers, such as gastric, hepatocellular cancer (HCC) and pancreatic cancer[29-33].

Recently, Cigrovski Berković et al[27] reported that the IL-1β -511 SNP contributes to the pNET susceptibility.

We conducted a case-control study to analyze IL-1β polymorphisms as risk factors for pNETs using germline DNA collected in a population-based case-control study of pancreatic cancer [51 pNET cases, 85 PDAC cases, 19 intraductal papillary mucinous neoplasm (IPMN) and 98 healthy controls] conducted in the Athens, Greece and Izmir, Turkey areas.

MATERIALS AND METHODS

Patients
The case-control study included 51 pNET cases (22
nonfunctional and 29 functional), 85 PDAC cases, 19 IPMN and 98 healthy controls (Table 1). None of the cases had a history of chronic pancreatitis. For subsequent analysis, we excluded cases and controls with known genetic syndromes (e.g., MEN1, MEN2, VHL or TSC). Controls were healthy blood donors with no evidence of inflammation. The diagnosis in all cases was established by standard procedures and confirmed histopathologically either from operatively resected tumors or biopsy tissues, in cases of unresectable tumors. Before commencement of the study, the Ethical committee at the participating centers approved the recruitment protocols. All participants were informed regarding the study, and their written consent was provided.

**Genotyping**

Genomic DNAs were isolated from peripheral ethylenediaminetetraacetic acid-treated blood of patients and healthy controls using the NucleoSpin Blood Kit (Macherey-Nagel, Germany). The IL-1β -511 C/T (rs16944) polymorphism was detected by PCR-RFLP using the set of primers: 5'-TGGCATTGATCTGGTTCATC-3' and 5'-GTTTAGGAATCTTCCCACTT-3'. The 35 cycles of PCR were carried out at 94 ℃ for 5 min, 94 ℃ for 1 min, 58 ℃ for 40 s and 72 ℃ for 5 min. Amplified PCR products were digested with AvaI for 2 h at 37 ℃. The fragments of 189- and 85-bp revealed homozygosity for the C allele, and 305-bp indicated homozygosity for the T allele.

The +3954 C/T (rs 1143634) polymorphism was detected with the 5'-TCAGGTGTCCTCGAAGAAATCAAA-3' and 5'-GGTTTTTTGCTGTGAGTCCC-3' set of primers and the cycling parameters for that was 94 ℃ for 5 min, 94 ℃ for 45 s, 56 ℃ for 45 s and 72 ℃ for 45 s and the final cycle of 72 ℃ for 5 min. After 35 cycles the PCR product were digested for 2 h at 65 ℃ with TaqI. The fragments of 97- and 85-bp revealed homozygosity for the C allele and on the other hand 182-bp fragments showed homozygosity for the T allele.

**RESULTS**

The clinicopathological characteristics of the studied population are summarized in Table 1. The genotype frequencies of the IL-1β -511 C/T and +3954 C/T polymorphisms between PDAC, pNET, IPMN patients and controls are given in Table 2. All genotype distributions were in Hardy-Weinberg equilibrium. The distribution of genotypes for the -511 C/T polymorphism in the pNET patient groups only showed significant difference compared to the control group. It is known that the carriers of the IL-1β -511T allele have increased concentrations of IL-1β[18]. The -511 CT and TT high-expression genotypes were over-represented in pNET patients (Table 2). However, the presence of the +3954T
allele seems to have a protective role in the pNET development since it is found to be over-represented in healthy controls. The haplotype analysis did not reveal any significant association. No significant association was found between genotypes, haplotypes, and clinicopathological data of the patients.

**DISCUSSION**

PNETs are a rare, heterogeneous group of neuroendocrine tumors. They usually have a better prognosis than the PDACs. The cause of these tumors is not fully understood, but differential expression of proinflammatory cytokines were found in pNET tissues\[^{19-21}\]. The findings of this study suggested a possible role of IL-1\(\beta\) -511 C/T genotypes in the pathogenesis of pNETs since the presence of the IL-1\(\beta\) -511 CT and TT genotypes and the T allele was associated with an increased risk of pNET only. None significant correlation was found with PDAC and IPMN cases. Although Barber et al\[^{30}\] reported that the +3954 C/T polymorphism of the IL-1\(\beta\) gene predisposes to pancreatic cancer; our findings did not reveal any significant association. Additionally, they are partly in agreement with the findings of Cigrovski Berkovic et al\[^{37}\], which suggest that there is an association between the IL-1\(\beta\) -511 C/T genotype and the susceptibility to pNET, especially functional pNETs. In our study we did not find any haplotype combination to be statistically associated with the susceptibility to pNETs, neither PDAC nor IPMN cases, but we observed that the +3954 T allele is over-represented among healthy controls compared to pNET cases suggesting that this allele might have a protective role in pNET development.

Carcinogenesis in the gastrointestinal tract and pancreas is often associated with chronic inflammation. The study provides evidence of a role of interleukin 1\(\beta\) (IL-1\(\beta\)) -511 C/T genotypes in the pathogenesis of pancreatic neuroendocrine tumors (pNETs).

**COMMENTS**

**Background**

Carcinogenesis in the gastrointestinal tract and pancreas is often associated with chronic inflammation. The study provides evidence of a role of interleukin 1\(\beta\) (IL-1\(\beta\)) -511 C/T genotypes in the pathogenesis of pancreatic neuroendocrine tumors (pNETs).

**Research frontiers**

PNETs are a rare, heterogeneous group of neuroendocrine tumors. They usually have a better prognosis than the pancreatic adenocarcinomas. The cause of these tumors is not fully understood, but differential expression of proinflammatory cytokines were found in pNET tissues. Identifying genetic factors associated basically with pNET incidence may help in the primary prevention of pNET across the globe.

**Innovations and breakthroughs**

The study suggested a possible role of IL-1\(\beta\) -511 C/T genotypes in the pathogenesis of pNETs since the presence of the IL-1\(\beta\) -511 CT and TT genotypes and the T allele was associated with an increased risk of pNET only.

**Applications**

The study contributes to elucidate the role of cytokines and inflammatory pathway in the sporadic pNET development.

**Terminology**

PNETs: Pancreatic neuroendocrine tumors; PDACs: Pancreatic adenocarcinomas; IPMN: Intraductal papillary mucinous neoplasm.

**Peer-review**

This is an interesting study that looks at IL-1\(\beta\) as a potential inflammatory biomarker of tumor exocrine differentiation\[^{29,43}\].

Our previous results suggested that TNF-\(\alpha\) -1031 polymorphism is associated with the development of pNET and IPMN\[^{41}\], and several studies supported that proinflammatory cytokines were detected in pNET tissues signifying their etiological involvement\[^{19,44}\]. Taken these into consideration future studies in larger populations are needed to elucidate the role of cytokines and inflammatory pathway in the sporadic pNET development.
cytokine stimulus for tumour formation in pNETs. While chronic inflammation is known to contribute to carcinogenesis, in the pancreas, this is peculiar to PDAC where association with chronic pancreatitis is not uncommon.

REFERENCES

1. Vortmeyer AO, Huang S, Lubensky I, Zhuang Z. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab 2004; 89: 1934-1938 [PMID: 15070966 DOI: 10.1210/jc.2003.031575]

2. Vayani S, Ouyang B, Bayraktar Y. Current medical treatment of pancreatic neuroendocrine tumors. Hepatogastroenterology 2007; 54: 278-284 [PMID: 17419276 DOI: 10.3390/cancers2031419]

3. Ehehalt F, Saeger HD, Schmidt CM, Grützmann R. Neuroendocrine tumors of the pancreas. Oncologist 2009; 14: 456-467 [PMID: 19411317 DOI: 10.1634/theoncologist.2008-0259]

4. Krampitz GW, Norton JA. Pancreatic neuroendocrine tumors. Curr Probl Surg 2013; 50: 509-545 [PMID: 24206780 DOI: 10.1067/cps.2013.08.001]

5. Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol 2012; 8: 54-64 [PMID: 21808296 DOI: 10.1038/nrendo.2011.120]

6. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2011; 18: 1-18, vii [PMID: 21349409 DOI: 10.1016/j.ece.2010.12.005]

7. Zikoska MN, Kidd M, Eick G, Latich I, Modlin IM. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 2005; 104: 2292-2309 [PMID: 16258976 DOI: 10.1002/cncr.21415]

8. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2010; 1204: 13-27 [PMID: 15153416 DOI: 10.1196/annals.1294.002]

9. Yao JC. Neuroendocrine tumors of the gastroenteropancreatic system. Surg Oncol 2007; 16: 915-933 [PMID: 17861484 DOI: 10.1016/s0960-0338(07)9004-4]

10. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135: 1469-1499 [PMID: 18703061 DOI: 10.1053/j.gastro.2008.05.047]

11. Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Relationship of the interleukin-1 system with neuroendocrine and exocrine markers in human colon cancer cell lines. Cytokine 2002; 18: 86-91 [PMID: 12096293 DOI: 10.1006/cyto.2001.1019]

12. Corbetta J, Wahl MI, Wang JL, Lancaster JR, McDaniel ML. Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. Proc Natl Acad Sci USA 1993; 90: 1731-1735 [PMID: 8338325 DOI: 10.1073/pnas.90.5.1731]

13. Apte RN, Dotan S, El-Omar EM, Cacev T, Catela Ivkovic T, Zajic-Rotkovic V, Kapitanovic S. New insights into the role of chronic inflammation and cytokines in the etiopathogenesis of gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology 2014; 99: 75-84 [PMID: 24686050 DOI: 10.1159/000362339]

14. Abdul M, Hoosein N. Relationship of the interleukin-1 system with neuroendocrine and exocrine markers in human colon cancer cell lines. Cytokine 2002; 16: 119-125 [PMID: 11711714 DOI: 10.1006/cyto.2001.0129]
cancer. *Nature* 2000; **404**: 398-402 [PMID: 10746728 DOI: 10.1038/35006081]

35 Wang Y, Kato N, Hoshida Y, Yoshida H, Taniguchi H, Goto T, Moriyama M, Otsuka M, Shiina S, Shiratori Y, Ito Y, Oma M. Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. *Hepatology* 2003; **37**: 65-71 [PMID: 12500190 DOI: 10.1053/jhep.2003.50017]

36 Barber MD, Powell JJ, Lynch SF, Fearon KC, Ross JA. A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. *Br J Cancer* 2000; **83**: 1443-1447 [PMID: 11076651 DOI: 10.1053/bjc.2000.1479]

37 Cigrovski Berković M, Catela Ivković T, Marout J, Zjačić-Rotkvić V, Kapitanović S. Interleukin 1β gene single-nucleotide polymorphisms and susceptibility to pancreatic neuroendocrine tumors. *DNA Cell Biol* 2012; **31**: 531-536 [PMID: 21988351 DOI: 10.1089/dna.2011.1317]

38 Chourasia D, Achyut BR, Tripathi S, Mittal B, Mittal RD, Ghoshal UC. Genotypic and functional roles of IL-1B and IL-1RN on the risk of gastroesophageal reflux disease: the presence of IL-1B-511*T/IL-1RN*1 (T1) haplotype may protect against the disease. *Am J Gastroenterol* 2009; **104**: 2704-2713 [PMID: 19603010 DOI: 10.1038/aig.2009.382]

39 Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. *Cancer Res* 2003; **63**: 3560-3566 [PMID: 12839942]

36 Barber MD, Powell JJ, Lynch SF, Fearon KC, Ross JA. A polymorphism of the interleukin-1 beta gene influences survival survival in pancreatic cancer. *Br J Cancer* 2000; **83**: 1443-1447 [PMID: 11076651 DOI: 10.1053/bjc.2000.1479]

35 Wang Y, Kato N, Hoshida Y, Yoshida H, Taniguchi H, Goto T, Moriyama M, Otsuka M, Shiina S, Shiratori Y, Ito Y, Oma M. Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. *Hepatology* 2003; **37**: 65-71 [PMID: 12500190 DOI: 10.1053/jhep.2003.50017]

36 Barber MD, Powell JJ, Lynch SF, Fearon KC, Ross JA. A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. *Br J Cancer* 2000; **83**: 1443-1447 [PMID: 11076651 DOI: 10.1053/bjc.2000.1479]

36 Barber MD, Powell JJ, Lynch SF, Fearon KC, Ross JA. A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. *Br J Cancer* 2000; **83**: 1443-1447 [PMID: 11076651 DOI: 10.1053/bjc.2000.1479]

36 Barber MD, Powell JJ, Lynch SF, Fearon KC, Ross JA. A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. *Br J Cancer* 2000; **83**: 1443-1447 [PMID: 11076651 DOI: 10.1053/bjc.2000.1479]

36 Barber MD, Powell JJ, Lynch SF, Fearon KC, Ross JA. A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. *Br J Cancer* 2000; **83**: 1443-1447 [PMID: 11076651 DOI: 10.1053/bjc.2000.1479]

36 Barber MD, Powell JJ, Lynch SF, Fearon KC, Ross JA. A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. *Br J Cancer* 2000; **83**: 1443-1447 [PMID: 11076651 DOI: 10.1053/bjc.2000.1479]

36 Barber MD, Powell JJ, Lynch SF, Fearon KC, Ross JA. A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. *Br J Cancer* 2000; **83**: 1443-1447 [PMID: 11076651 DOI: 10.1053/bjc.2000.1479]

36 Barber MD, Powell JJ, Lynch SF, Fearon KC, Ross JA. A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. *Br J Cancer* 2000; **83**: 1443-1447 [PMID: 11076651 DOI: 10.1053/bjc.2000.1479]

36 Barber MD, Powell JJ, Lynch SF, Fearon KC, Ross JA. A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. *Br J Cancer* 2000; **83**: 1443-1447 [PMID: 11076651 DOI: 10.1053/bjc.2000.1479]
